

Table 1. Demographics, characteristics and immunological profile of study population.

Variable	Result (n=64)
Age, median (IQR), years	40.5 (30–56)
Sex, no. (%)	
Female	46 (72%)
Male	18 (28%)
Ethnicity, no. (%)	
Chinese	46 (72%)
Malay	10 (16%)
Indian	5 (8%)
Others	3 (5%)
Brand of vaccine to which reaction occurred, no. (%)	
Pfizer-BioNTech	59 (92%)
Moderna	5 (8%)
Dose of vaccine to which reaction occurred, no. (%)	
1st	49 (77%)
2nd	12 (19%)
3rd	3 (5%)
Atopy history, no. (%)	
Any atopy history	47 (73%)
Chronic spontaneous urticaria	29 (45%)
Asthma	7 (11%)
Allergic rhinitis	12 (19%)
Eczema	10 (16%)
Food allergy	16 (25%)
Drug allergy	20 (31%)
Family history of atopy, no. (%)	13 (20%)
Timing and severity of reaction, no. (%)	
Immediate onset, mild	10 (16%)
Immediate onset, moderate-to-severe	9 (14%)
Delayed onset, mild	14 (22%)
Delayed onset, moderate-to-severe	31 (48%)
Development of chronic spontaneous urticaria post-vaccination, no. (%)	12 (19%)
Immunological biomarkers	No. (%) of patients with elevated biomarkers (n=13)
IL-6	5 (38%)
IL-18	13 (100%)
IFN- γ	12 (92%)
CRP	4 (31%)
MCP-1	6 (46%)
IL-4, IL-5, IL-10, TNF- α , ICAM-1, C5a	0

C5a: complement 5a; CRP: C-reactive protein; ICAM-1: intercellular adhesion molecule; IFN: interferon; IL: interleukin; IQR: interquartile range; MCP-1: monocyte chemoattractant protein; TNF: tumour necrosis factor